Navigation Links
Biodel Inc. Added to NASDAQ Biotechnology Index
Date:5/13/2008

DANBURY, Conn., May 13 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective as of the market's open on Monday, May 19, 2008.

"We are pleased to be included in the NASDAQ Biotechnology Index and believe Biodel's inclusion is a result of the Company's consistent achievement of its goals," stated Dr. Solomon Steiner, Chairman and Chief Executive Officer of Biodel. "We look forward to reporting on future 2008 goals including the results from our two pivotal Phase III clinical trials for VIAject(TM) in September or October and the filing of our NDA submission for a suite of VIAject(TM) presentations by the end of 2008."

Launched in 1993, the NBI includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology Index Fund (Amex: IBB). For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
2. Biodel Inc. to Present at the Bank of America 2008 Health Care Conference on May 13th 2008
3. Biodel Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference April 30th 2008
4. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
5. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
6. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
7. Biodel Inc. Announces Pricing of Public Offering
8. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
9. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
10. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
11. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... for more than 150 years, continues today to pursue the highest level of ... of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... Early-career researchers from Indonesia , ... Uganda and Yemen honored ... Indonesia , Nepal , ... are being honored for their accomplishments in nutrition, psychiatry, biotechnology, ... young women scientists who are pursuing careers in agriculture, biology and medicine ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
Breaking Biology Technology:
(Date:1/20/2016)... 2016 A market that just keeps on ... the explosion in genomics knowledge. Learn all about it ... range of dynamic trends are pushing market growth and ... - pharmacogenomics - pathogen evolution - next generation sequencing ... greater understanding of the role of genetic material in ...
(Date:1/15/2016)... Puerto Rico , Jan. 15, 2016 ... big and small to find new ways to ensure ... culture. iOS and Android ... based on biometrics, transforming it into a hardware authorization ... that users swipe their fingerprint on their KodeKey enabled ...
(Date:1/11/2016)... 2016  higi, the leading retail and omni-channel community ... web and mobile, today announced it has closed ... investors. --> --> ... innovate higi,s health platform – its network of ... including expanding services and programs to retail partners ...
Breaking Biology News(10 mins):